scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Vaccine delivery using nanoparticles

TL;DR: N nanoscale size materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antIGens and act as adjuvants, thereby modulating the immune response to the antigen.
Abstract: Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens.

Content maybe subject to copyright    Report

Citations
More filters
28 Jul 2005
TL;DR: PfPMP1)与感染红细胞、树突状组胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作�ly.
Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1(PfPMP1)与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员,通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

18,940 citations

Journal ArticleDOI
TL;DR: This review systematizes and summarizes available data on how the mechanisms of NP toxicity for living systems are related to their physical and chemical properties.
Abstract: Studies on the methods of nanoparticle (NP) synthesis, analysis of their characteristics, and exploration of new fields of their applications are at the forefront of modern nanotechnology. The possibility of engineering water-soluble NPs has paved the way to their use in various basic and applied biomedical researches. At present, NPs are used in diagnosis for imaging of numerous molecular markers of genetic and autoimmune diseases, malignant tumors, and many other disorders. NPs are also used for targeted delivery of drugs to tissues and organs, with controllable parameters of drug release and accumulation. In addition, there are examples of the use of NPs as active components, e.g., photosensitizers in photodynamic therapy and in hyperthermic tumor destruction through NP incorporation and heating. However, a high toxicity of NPs for living organisms is a strong limiting factor that hinders their use in vivo. Current studies on toxic effects of NPs aimed at identifying the targets and mechanisms of their harmful effects are carried out in cell culture models; studies on the patterns of NP transport, accumulation, degradation, and elimination, in animal models. This review systematizes and summarizes available data on how the mechanisms of NP toxicity for living systems are related to their physical and chemical properties.

612 citations


Cites background from "Vaccine delivery using nanoparticle..."

  • ...This allows obtaining vaccines against the antigens that are targets of strong natural nonspecific cellular immunity [99]....

    [...]

Journal Article
TL;DR: Expectations regarding nanodrugs that are in early stages of development or clinical trials need to remain realistic because of the need for better characterization and the lack of specific regulatory guidelines.
Abstract: Nanomedicine is a relatively new and rapidly evolving field combining nanotechnology with the biomedical and pharmaceutical sciences.1-3 Nanoparticles (NPs) can impart many pharmacokinetic, efficacy, safety, and targeting benefits when they are included in drug formulations.1-5 Many nanodrugs have entered clinical practice, and even more are being investigated in clinical trials for a wide variety of indications.2 However, nanopharmaceuticals also face challenges, such as the need for better characterization, possible toxicity issues, a lack of specific regulatory guidelines, cost-benefit considerations, and waning enthusiasm among some health care professionals. 4,5 For these reasons, expectations regarding nanodrugs that are in early stages of development or clinical trials need to remain realistic.4.

453 citations

Journal ArticleDOI
11 Jul 2014
TL;DR: This review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines.
Abstract: Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have become important carrier systems in vaccine development and the interest for liposome-based vaccines has markedly...

389 citations


Cites background from "Vaccine delivery using nanoparticle..."

  • ...Strength and mechanisms of immunostimulation induced by nanocarrier vaccines depend on various factors, such as chemical composition, particle size and homogeneity, charge, nature and location of antigens and/or adjuvants within the carrier and, last but not least, the site of administration (see Figure 2) [Watson et al. 2012; Brito et al. 2013; Gregory et al. 2013; Smith et al. 2013; Zaman et al. 2013]....

    [...]

Journal ArticleDOI
TL;DR: About this specific diversity of particulates, the different elaboration methodologies, mandatory and elementary components for design, and examples of splendid success stories for these particulates were emphasized in this humble review.

383 citations


Cites background from "Vaccine delivery using nanoparticle..."

  • ...By using PNPs to carry antigens, the uptake effectiveness into dendritic cells is considerably amplified compared with the free antigen (Gregory et al., 2013)....

    [...]

References
More filters
28 Jul 2005
TL;DR: PfPMP1)与感染红细胞、树突状组胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作�ly.
Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1(PfPMP1)与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员,通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

18,940 citations

Journal ArticleDOI
TL;DR: In this paper, a preliminary survey with the electron microscope of various preparations of colloidal gold, a study was made of the process of nucleation and growth in gold colloids, and it was shown that nucleating agents may be identified with reducing agents which form a mixed polymer with chlorauric ion before the reduction to the nucleus takes place.
Abstract: After a preliminary survey with the electron microscope of various preparations of colloidal gold, a study was made of the process of nucleation and growth in gold colloids. It was shown that nucleating agents may be identified with reducing agents which form a mixed polymer with chlorauric ion before the reduction to the nucleus takes place. It was also shown that the law of growth is exponential. The average size, the deviation from the average size and the character of the particle size distribution curve are determined by the amount of gold, the nucleation process and the law of growth.

6,593 citations


"Vaccine delivery using nanoparticle..." refers background in this paper

  • ...The smaller particles, formed from using a strong reducing agent, can then be grown to form larger particles with a desired aspect ratio using ceyltrimethlammonium bromide and silver acetate (Turkevich et al., 1951; Bhumkar et al., 2007a; Zhou et al., 2008; Chen et al., 2010)....

    [...]

Journal ArticleDOI
TL;DR: The intracellular uptake of different sized and shaped colloidal gold nanoparticles is investigated and it is shown that kinetics and saturation concentrations are highly dependent upon the physical dimensions of the nanoparticles.
Abstract: We investigated the intracellular uptake of different sized and shaped colloidal gold nanoparticles. We showed that kinetics and saturation concentrations are highly dependent upon the physical dimensions of the nanoparticles (e.g., uptake half-life of 14, 50, and 74 nm nanoparticles is 2.10, 1.90, and 2.24 h, respectively). The findings from this study will have implications in the chemical design of nanostructures for biomedical applications (e.g., tuning intracellular delivery rates and amounts by nanoscale dimensions and engineering complex, multifunctional nanostructures for imaging and therapeutics).

4,383 citations


"Vaccine delivery using nanoparticle..." refers background in this paper

  • ...The results showed that the optimal size for uptake was 50 nm and uptake increased significantly for the first 2 h before plateauing at between 4 and 7 h post-exposure (Chithrani et al., 2006)....

    [...]

Journal ArticleDOI
TL;DR: This review presents the most outstanding contributions in the field of biodegradable polymeric nanoparticles used as drug delivery systems from 1990 through mid-2000.

3,284 citations


"Vaccine delivery using nanoparticle..." refers background in this paper

  • ...One of the greatest obstacles with liposome delivery systems is their instability (Soppimath et al., 2001; Hans and Lowman, 2002)....

    [...]

Journal ArticleDOI
TL;DR: The data indicate that the size itself of (ligand-devoid) particles can determine the pathway of entry in non-phagocytic B16 cells, and kinetic parameters may determine the almost exclusive internalization of such particles along this pathway rather than via caveolae.
Abstract: Non-phagocytic eukaryotic cells can internalize particles <1 microm in size, encompassing pathogens, liposomes for drug delivery or lipoplexes applied in gene delivery. In the present study, we have investigated the effect of particle size on the pathway of entry and subsequent intracellular fate in non-phagocytic B16 cells, using a range of fluorescent latex beads of defined sizes (50-1000 nm). Our data reveal that particles as large as 500 nm were internalized by cells via an energy-dependent process. With an increase in size (50-500 nm), cholesterol depletion increased the efficiency of inhibition of uptake. The processing of the smaller particles was significantly perturbed upon microtubule disruption, while displaying a negligible effect on that of the 500 nm beads. Inhibitor and co-localization studies revealed that the mechanism by which the beads were internalized, and their subsequent intracellular routing, was strongly dependent on particle size. Internalization of microspheres with a diameter <200 nm involved clathrin-coated pits. With increasing size, a shift to a mechanism that relied on caveolae-mediated internalization became apparent, which became the predominant pathway of entry for particles of 500 nm in size. At these conditions, delivery to the lysosomes was no longer apparent. The data indicate that the size itself of (ligand-devoid) particles can determine the pathway of entry. The clathrin-mediated pathway of endocytosis shows an upper size limit for internalization of approx. 200 nm, and kinetic parameters may determine the almost exclusive internalization of such particles along this pathway rather than via caveolae.

2,613 citations